Tag Archives: treatment

‘Treatment for rare skin condition affecting fingers lies in the palm of your hand’

Have you ever heard of the ­condition Dupuytren’s contracture, which gradually causes the fingers to close in on the hand? I was reminded of it by a recent report in the British Medical Journal, and a relative of mine had the ­condition so I could study it in detail and over time. It’s estimated between… Read More »

FDA Approves Livmarli (maralixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

[unable to retrieve full-text content]FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 29, 2021– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Livmarli (maralixibat) oral solution for… Drugs.com – New Drug Approvals

FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD)

[unable to retrieve full-text content]WILMINGTON, Del.–(BUSINESS WIRE) September 21, 2021 — Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the short-term and non-continuous chronic treatment of… Drugs.com – New Drug Approvals

Essential Reads: Bright Light Therapy for the Treatment of Depression During Pregnancy, Mixed Findings

Despite data to support the reproductive safety of many antidepressants during pregnancy, many women would prefer to avoid medications, if possible.  In this setting, many women pursue psychotherapy, others use acupuncture or yoga or exercise. Although non-pharmacologic treatments are perceived as being safer than medications, this is only true if the treatment is effective.  Exposure… Read More »

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) BOSTON, July 20, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in… Read More »